EuMentis Therapeutics Inc. is a privately held biopharmaceutical company focused on developing novel
therapies to treat high value neurodevelopmental and neurodegenerative diseases. The Company’s lead
program, EM-036, is a nitro-aminoadamantane N-methyl-D-aspartate (NMDA) receptor antagonist in
preclinical development for the treatment of multiple CNS diseases including Alzheimer’s Disease and
Autism-Spectrum Disorders...
EuMentis Therapeutics Inc. is a privately held biopharmaceutical company focused on developing novel
therapies to treat high value neurodevelopmental and neurodegenerative diseases. The Company’s lead
program, EM-036, is a nitro-aminoadamantane N-methyl-D-aspartate (NMDA) receptor antagonist in
preclinical development for the treatment of multiple CNS diseases including Alzheimer’s Disease and
Autism-Spectrum Disorders. Preclinical data to date demonstrate significant improvement in efficacy of
EM-036 over Namenda® in Alzheimer's Disease and Autism-Spectrum Disorder models with no safety
issues.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.